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Abstract 
Background: South Africa has a high tuberculosis burden, and Limpopo Province experienced higher than national average 
TB mortality rates between 1997 and 2008.
Objective: To establish factors associated with TB mortality in Limpopo Province in 2008.
Design: Retrospective  study using provincial data for patients who died after commencing TB treatment between 01 Janu-
ary 2008 and 31 December 2008.
Results: In 2008, some 18074 patients started treatment:  15995 (88.5%)  had pulmonsry TB (PTB), while 2079 (11.5%) had 
Extra pulmonary TB (EPTB).  Overall,  2242  (12.4%)  patients  died,  mainly  PTB  patients  (n=1906;
85%), more males (n=1159, 51.7%), mainly those aged 25 to 54 years (n=1749, 78.0%), and new cases (1914; 85.4%). TB 
mortality was significantly higher among smear negative than smear positive  patients (17% vs 13.8%;  P<0.001),  among 
those with EPTB compared  to PTB  patients  (P<0.001),  and  among re-treatment  cases  (P<0.001).    Only  4237 
(23.4%) patients had HIV status known, with higher mortality found among HIV positive than the HIV negative patients 
(P<0.0001);  but HIV status was not known for the majority who died (n=1685, 75.2%).
Conclusion: Higher mortality was associated with age 22-55 years; smear negativity, EPTB, HIV  infection,  and  re-treat-
ment.  The  findings  call  for greater integration  of    TB control efforts and HIV services,  especially  among the 22-55 year 
age group. 
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Introduction
South Africa was ranked fifth among the 22  tubercu-
losis (TB) high burden countries in 2007 and third af-
ter India and China among the 22 countries carrying 
82% of  global TB burden in 20101. According to the 
World Health Organization  (WHO) Global TB Report 
2009, South Africa had nearly 460 000 new TB cases in 
2007 with an incidence rate of  948 cases per 100 000 
population,  and a TB prevalence  rate of  692 per 100 
000 population  per year2. South Africa has the larg-
est  number  of  people living with human immunode-
ficiency  virus (HIV) and  acquired immune deficiency 
syndrome (AIDS), as a result HIV associated TB has 
become  a major  clinical  and  public  health  problem3. 
The  (HIV) epidemic that has progressed  in tandem 
with TB infection poses a big threat to TB Control ef-
fort4,5.
Limpopo is one of  the poorest provinces of  South 
Africa, with relatively poor infrastructure and public 
services, including health. The province has a vibrant 
TB Control Programme that works  according  to the 
national  guidelines,  including  the capture  of  TB sta-
tistics  on the electronic database, ETR.Net. Program-
matic data shows that the recorded number of  TB cases 
in the Limpopo Province increased more than threefold 
from 6286 in 2000 to 22836 in 2009. However, the bac-
teriological coverage decreased from 90.7% to 79.9% 
over the same period. At the same time, the death rate 
in new smear positive patients in the province was con-
sistently higher than the national average between 1997 
and 2008.
The Desmond Tutu TB Centre, University of  Stellen-
bosch, in collaboration with the National Department 
of  Health, is coordinating efforts to strengthen the 
capacity of  the provinces to conduct operations re-
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search on TB. In this context, the Limpopo Province 
team undertook a study on the high death rates among 
TB patients on treatment, with a view to contribute to 
understanding  the factors responsible for the high TB 
mortality rate in the province.  “Died” was taken to re-
fer to a TB client who died from any cause during treat-
ment, according to WHO guidelines. The aim of  the 
study was to assess the factors associated with mortality 
among TB patients who started treatment between 01 
January and 31 December 2008.
Study design
Methodology 
This was a quantitative,  retrospective  study using ETR.
Net  provincial data for patients who  initiated  TB  treat-
ment  from 1  January  2008  to  31  December  2008. 
The data were imported  from ETR.net  to Microsoft 
Excel, using a data capture template that was developed 
for that purpose. The data were then analysed to estab-
lish the TB mortality for the year, and the characteristics 
of  patients who died.
Study population
All TB patients who died after starting treatment from 
1 January until 31 December  2008 were included in the 
study.
Data collection
The  age  and  sex  of   patients  that  died  after  com-
mencement  of   treatment  in 2008  were recorded.  The 
association  between  smear  positivity  and outcome 
were analysed  using a 2X2 table matching smear posi-
tivity and outcome. Where the diagnosis was confirmed 
by culture, that was recorded; and where sensitivity was 
tested, the results were captured as well, including men-
tion of  MDR/XDR TB where applicable. The HIV 
status was recorded as HIV positive, HIV negative or 
no HIV test done, and among those who were HIV 
positive, any additional information, such as CD4 cell 
count, and whether or not they were on HAART was 
also noted.  The site of  disease was recorded as pulmo-
nary, extra-pulmonary,  or both; while  the  diagnostic 
category  was  recorded   as  new  patient  or  retreat-
ment,   and  for retreatment  this  was  noted  as after 
default  or relapse,  or some  other  form  of  treatment 
failure.
Statistical analysis
Summary statistics were generated using Microsoft Ex-
cel, while SPSS version 20 was used for further analysis 
of  the data for association between various variables 
and TB mortality. The association between variables 
and mortality was tested using the Chi-square test and 
post hoc Bonferroni’s correction, with P< 0.05 as the 
limit of  significance.
Ethical considerations
The  study  protocol  was  approved  by  the  University 
of   Limpopo  Polokwane-Mankweng Research  Ethics 
Committee.  In  addition,  permission   was  obtained 
from  the  Limpopo Province  Department  of   Health 
and  Social  Development  Research  Committee,  and 
the proposal was further reviewed and approved by 
the International Union against TB and Lung Diseases 
(IUATLD) prior to commencement of  the study. This 
was a non-intrusive study that utilized retrospective 
data;  .  All data captured were without specific patient 
identifiers, to ensure the anonymity of  the patients  , 




A  total  of   18074  patients  (52.3%  male)  started 
treatment  during  the  year  2008;   .  Of  those  15995 
(88.5%)  had pulmonary  TB, while 2079 (11.5%)  had 
extra pulmonary TB; 16013 (88.6%) were new cases, 
964 (5.3%) were relapses, 622 (3.4%) had previously de-
faulted,  288 (1.6%)  had  a history of  treatment  failure, 
and 187 (1.0%)  were  “all other retreatment”  cases. 
The number of  deaths recorded for the period under 
review was 2242 (12.4%), being 1083 (48.3%) female 
and 1159 (51.7%)  male, with no gender-related differ-
ence in TB mortality.
As shown in Figure 1, most of  those who died (78%) 
were aged 25 to 54 years, while Figure 2  shows  that 
increasing  age  was  associated  with  increased  likeli-
hood  of   death  for  TB patients on treatment (Χ2 = 
180.1; df=5; P<0.0001).
Figure 1:  The respective figures were 94 (4.2%) patients 
were aged 4 years and below, 42 (1.9%) were aged 5 
to 14 years, 116 (5.2%) were aged 15-24 years, 1652 
(78.0%) were 25 to 54 years, 281 (12.5%) were 55 to 74 
years, and 57 (2.5%) were older than 75 years. 
New cases accounted for 85.4% (n=1914) of  total 
mortality, while 146 (6.5%) deaths were relapsed  PTB 
cases,  104 (4.6%)  were those who had previously  de-
faulted  treatment;  45 (2.0%) had history of  treatment 
failure; and 31 (1.4%) were other retreatment cases. 
Proportionately, 12% of  the new cases died compared 
to 15.1% of  the relapse cases, 16.7% of  those with a 
history of  defaulting,  15.6% of  those with history of  
treatment  failure, and 16.6%  of  those  categorised  as 
“others”.  The  likelihood  of   death  was  significantly 
higher among  retreatment  cases  than  among  the 
new  cases  (Χ2   =  21.8;  df   =  1;  P<0.001). Regard-
ing treatment regimens, most of  the patients (79.3%) 
were on Regimen 1 (2RHZE +4HR; N=1777); while 
323 (14.4%) were on Regimen 2 (2RHZES + 1 RHZE 
+ 5HRE); 108 (4.8%)  were  on  Regimen  3  (paediatric 
2RHZ  +  4HR);  and  34  (1.5%)  were  on  others treat-
ment, including chemotherapy.  There was a significant 
association between treatment regimen and TB mortal-
ity: those on Regimen 2 (re-treatment)  were more likely 
to die than were new cases on Regimen 1 (17.2% vs 
11.1%;  Χ2 = 45. 7; df=1; P<0.001).
Figure 2: TB mortality within the age groups increased 
with age, with the groups 24 years and below recording 
less than 10% mortality rate (8.4 among those aged 4 
years and below, 4.7% among those aged 5 to 14 years, 
and 5.5% among the 15-24 year group); while those 
aged 25 years and above had mortality rates higher than 
10% (13.8% among the 25 to 54 years, 15.7% among 
the 55 to 74 year group , and 23.3% among those older 
than 75 years.
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The  majority  of   TB  deaths  (n=1906,  85%)  had 
PTB;   ,  319  (14.2%)  had  extra- pulmonary  TB;  ,15 
(0.7%)  had both PTB and EPTB,  whilst  for two pa-
tients  (n=2, 0.1%) the site of  disease was not recorded. 
The mortality rate among those with PTB was 11.9% 
and 16.1%  among  those with EPTB;  . While  EPTB 
contributed  to 11.5%  of  the recorded TB cases un-
der review, the category contributed to 16.1% of  the 
mortality in that year.  , thus  patients  with EPTB were 
more likely to die than those with PTB (Χ2  =28.8; 
df=1; P<0.001).
Among  the 15995  PTB patients,  9003 (56.3%)  were 
smear  positive,  1828  (11.4%)  were smear  negative 
and  5164  (32.3%)  had  no  smear  results  record-
ed,  for  a  bacteriological coverage of  73%. Among 
those with known sputum smear results (N=10831), 
the mortality rate was 17% among smear negative pa-
tients, compared to 13.8% among smear positive pa-
tients. There was higher mortality among smear nega-
tive PTB patients than among the smear positive ones 
(Χ2  = 12.5; df=1; P<0.001). Among smear positive 
patients that died, there was no apparent difference in 
sputum conversion rates between new smear positive 
and retreatment smear positive patients, suggesting that 
in smear positive cases the mycobacteria remained sen-
sitive to the standard regimen for each category.
Only 4237 (23.4%) of  the cases recorded in 2008 had 
their HIV status known, and of  these 2812 (66.4%) were 
HIV positive while 1425 (33.6%) were HIV negative. 
Among those that were HIV positive, 1362 (48.4%) had 
smear positive PTB, 379 (13.5%) had smear negative 
TB, in 698 (24.8%) cases no smear was done; and 373 
(13.3%) had EPTB. Among those that died with known 
HIV status (n=557), 83.5% (n=465) were HIV posi-
tive, while 92 (16.5%) were HIV negative. The majority 
of  those that died (n=1746, 77.9%) did not have HIV 
status recorded, but where it was established the HIV 
positive patients were more likely to die than the  HIV 
negative  patients  (P<0.0001).  It  was  not  possible 
to  disaggregate  the  data  to establish what proportion 
of  the HIV positive patients that died were on ART or 
CPT, and those that had had CD4 tests done.
Discussion
Limpopo Province recorded a TB mortality rate of  
12.4% for the year under review, with the majority  of  
deaths  recorded  among  the  economically  active  age 
group  (25-54  years). Mortality was significantly asso-
ciated with older age, extra pulmonary site of  disease, 
HIV co- infection; smear negative PTB and previous 
history of  TB.  These findings are consistent with pre-
vious reports on higher risk of  death associated with 
negative sputum smear, HIV co-infection and other co-
morbidities, and older age5-8.
The association between HIV infection and TB mortal-
ity was evident in the present study: HIV positive pa-
tients were more likely to have EPTB and more likely to 
be smear negative, and  mortality   was  higher   among 
those   who   were   HIV  positive.   Unfortunately,   HIV 
counselling  and testing (HCT) was done in less than a 
quarter of  the patients that started treatment that year, 
hence the full impact of  HIV infection on TB mortal-
ity in this setting HIV integrated services, it is apparent 
from the findings here-in presented that HCT and/or 
uptake of  HIV testing for TB patients may not have 
been  as widespread as envisaged by established guide-
lines. Higher TB mortality among those who are HIV 
infected has been reported by others 9-11. The low lev-
els of  HIV testing in TB patients means that many of  
those who may benefit from HAART are missed out, 
and yet HAART has been shown to improve treatment 
outcomes in HIV infected persons with TB12.   More-
over, as suggested by Nahed et al13, TB patients with 
HIV infection may require longer than standard therapy 
to avoid relapses or treatment failure13. Clearly, in order 
for those who are TB-HIV co-infected to benefit from 
interventions such as co-trimoxazole preventive thera-
py (CPT) and HAART as advocated by WHO1, there 
must be HIV testing among all TB patients and intensi-
fied case-finding for TB among people living with HIV. 
Efforts in this regard need to be strengthened in the 
Limpopo Programme in order for the province to meet 
the global targets of  all TB patients tested for HIV, and 
all TB patients living with HIV provided with and anti-
retroviral therapy, and isoniazid preventive therapy for 
HIV positive people without active TB1.
There were more males among those that died, which 
is explicable from the larger number of   males  among 
the  recorded  patients  for  the  year  under  review. 
Similarly, the highest number of  TB patients recorded 
was in the age group 25-54 years, and so were the ma-
jority of  those who died. This age group is the most 
economically active population, so such high morbidity 
and mortality has to be addressed to mitigate the pos-
sible negative impact on human development.  The  25-
54  year  age  group  is  also  the  one  most  affected  by 
HIV infection,  and  it  is  likely  that  TB-HIV  co-infec-
tion  is partly  responsible  for  both  the  high morbidity 
and mortality in that age group.  The preponderance of  
new cases in the province, and among those who died, 
suggests measures to curb TB transmission    were not 
effective, and that the population was not sensitized to 
seek treatment early.
Patients  that  were  on  retreatment  had  higher  mor-
tality  than  the  new  cases,  which  is consistent with 
findings from Kwa-Zulu Natal14. Indeed the retreat-
ment regimen remains of  questionable efficacy14,15. The 
programmatic implication of  this finding is that strate-
gies such as DOTS should be promoted and adherence 
enforced to avoid default and treatment failure which 
necessitate retreatment with less effective regimens.
The lack of  data on smear grading and culture and sen-
sitivity, the high number of  PTB cases with no smear 
results (32.4%), and the low rate of  HIV  testing were 
limitations of  the study. The lack of  microbiological 
data is not unique to the Limpopo TB Control Pro-
gramme, similar observations  have been made by 
others8,11; indeed, Komati et al view this as an Africa-
wide problem11. Limpopo-specific  challenges often in-
clude systemic reasons such as sputum not collected for 
diagnosis, and inaccessibility of  laboratory diagnostic 
facilities in the resource constrained settings many of  
the facilities operate under.
On the basis of  the above findings, the Limpopo TB 
Control Programme should intensify efforts to offer 
HIV counselling and testing to all TB patients, and to 
screen all HIV/AIDS patients for TB, in line with the 
policy of  the South African National Department of  
Health and Limpopo Province Department as well. The 
overarching recommendation is for the strengthening 
of  the integrated management of  TB and HIV patients, 
which would cover all the options such as early com-
mencement of  ART regardless of  CD4 count in those 
with TB-HIV co-infection and CPT.
Conclusion
There was higher TB mortality among the economi-
cally active age group and older patients, among those 
who were HIV positive, those that had smear negative 
PTB, those with EPTB, and among those on retreat-
ment  than for the other categories  of  TB patients. 
HIV testing was fairly low for the TB patients, which 
suggests that there is need to intensify HIV testing in 
TB patients in order to offer supportive therapy such as 
CPT and ART.
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